Good news for the unvaccinated

November 25, 2021

What is happening in the Danish society?
Denmark is a wonderful country! One must look for a long time for a more tolerant, incorruptible and trusting people!
So far, most Danes can probably agree.

Therefore, we can not help but ask: What is happening in our country right now?
Are we talking about an A-team and a B-team? The vaccinated and the UN-vaccinated? Yes, according to the Danish Prime Minister, we are!
It is disrespectful, and we must go far back in history to see such state-run disgrace of a minority.
And is it at all true that the unvaccinated are a danger and “live life dangerously”? Let’s look at the facts.

We can ourselves
Every day in our lives where we are symptom-free (healthy), it is not due to the absence of viruses or bacteria, but to the presence of an active, balanced immune system that does exactly what it is designed for.
– And which no vaccine can replace.

When health professionalism became politics
Lack of knowledge and misinformation of the population has led to an unjustified fear of viruses and an equally unjustified one-sided focus on vaccines. But worse still, it has created a disunion in the population.

That politicians, agencies, government officials, health professionals, and the general public have been convinced that infection is the same as disease is spin and politics and not health science.

A high infection rate does not matter if there are no patients. When 1,000 persons are infected without anyone dying, it means that 1,000 persons gain natural, strong immunity.
So when the Danish National Board of Health now reduces the duration of natural immunity from 12 to 6 months in the corona passport, then that policy is contrary to science.

If we observe the total mortality in Denmark over the past 20 years, we can state that mortality had not increased in 2020, when we had an epidemic at full strength, but no vaccines.
Covid-19 has thus not increased mortality in Denmark.

Furthermore, we can state that mortality has not decreased in 2021 (January to October), where we have vaccinated 80% of the population and 90% of the risk groups.
The vaccines have thus not reduced mortality in Denmark.

Even the number of infections today is much higher than it was the same day a year ago, although fewer are being tested now.
Thus, the vaccines have not reduced the number of infections either.

Why do some people’s immune system fail?
A groundbreaking study from the University of Copenhagen (KU) showed that vitamin D is necessary for our ability to survive infections in the normal way. The findings of the study were evaluated by the University of Copenhagen and determined to be so important that “a number of immunology books must be rewritten“.

Vitamin D in sufficient amounts is crucial for activating the immune system in infections, and “switching it off” again afterwards, so that the immune response is normalized.
The study explains the mechanism that has been sought in 50-60 years of vitamin D research.
The informed reader of the previous newsletters is well aware that in the absence of certain micronutrients, the immune system will fail.

Such a deficiency can not be remedied by simply taking the doses that are currently recommended here in Denmark. These are often too low because they do not take into account poor diet, improper preparation of food, stress, smoking, medication, etc., which leads to a greater need for these nutrients.
With a healthy lifestyle and a sufficient intake of the vitamins and minerals that are crucial for the immune system to function as it should, virtually no virus will be generally dangerous to the population in countries with Danish living standards.

Is vaccine our only salvation?
As the vaccine does not prevent infection or transmission, but should only inhibit serious illness in the vaccinated person, it is inconceivable that one wants to vaccinate healthy children who do not risk serious illness. The risk of vaccine side effects and death will here be far greater than the risk of the disease that the vaccine should protect against. This is contrary to The Hippocratic Oath.

Vaccines and only vaccines have been heavily targeted. Not a word about natural, effective, inexpensive and side-effect-free prevention and treatment.
It is like a three-legged stool, where the two legs have been removed, namely prevention and treatment.
Such a one-legged stool will never be able to stand alone.

It therefore surprises us that information about the things that can actually prevent and treat serious illness is not disseminated to the population through the official channels, but on the contrary is censored in a fog of misinformation.

We find it responsibility incurring not to inform about this.

Natural immunity – our main defense
We hear again and again the same experts on TV and in other media repeating that our immunity decreases at the same rate as the amount of antibodies in the blood, both after vaccination and after natural immunity after a viral infection. But this is wrong. A scientifically incorrect assumption. And a misunderstanding. With natural immunity, the amount of antibodies decreases naturally, after a viral infection. It should actually drop.

The wise body
The body is energy efficient and does not use energy and space to maintain high levels of antibodies to a virus it has just fought or the thousands of virus types we are constantly exposed to.
Once the virus has been defeated, the body turns down the flame so that it can again use energy on other processes. And it can do so calmly, because with the infection the natural, strong and often lifelong immunity is built up.
If, after battling the infection, the body continues to maintain high levels of antibodies in the blood for months and years, it is equivalent to a boxer who has just knocked out his opponent in the boxing ring continuing to walk with the parades up for months. That does not make sense.

The important memory cells
In the event of a viral infection, there is an activation of e.g. memory cells, which are coded to be able to recognize the virus they have just been in contact with, so that they can reactivate antibodies again very quickly at later encounters with the virus.

Unlike vaccine immunity, natural immunity is longer lasting, more broad-spectrum and thus more effective against mutations.

The continuous updating of the cells’ memory by natural immunity after infection makes the immune system stronger after each update. This ongoing update does not occur to the same extent with vaccine immunity, where one instead has to revaccinate.

This has just been demonstrated in a new study from August 2021 from Rockefeller University that specifically examines Pfizer’s and Moderna’s mRNA vaccines against natural immunity and has been confirmed by previous studies.

Updated memory cells can quickly activate an immune response adapted to the inevitable re-infections.
The reaction is rapid and the virus is therefore killed before it has time to multiply in an amount that triggers disease symptoms.
This means that we do not detect these recurrent re-infections. In other words, we are symptom-free and healthy, even though from time to time there is a disease virus in the body, and if we are tested for re-infection, it will be possible to measure the virus, and we are thus “infected”, ie. have a positive test. But we are neither sick nor particularly contagious.
Infection rates as a disease indicator are therefore a wrong strategy.

If there was a pandemic with a generally dangerous disease with high mortality (such as Ebola), and there was an effective and proven safe vaccine, then we would all be vaccinated, right?
But something lags. For none of these things are the case.

And it does not increase confidence in authorities, experts and the health system that there can be no calm, open and uncensored debate on these things.

Take care of yourself and others.

Kim Varming, Chief Physician and Clinical Immunologist,
Claus Hancke,
Specialist in General Medicine and
Michael Schultz,
Physiotherapist and Business Lawyer

Note: This post has in a slightly different form been published as a column in media in the northern part of Jutland 15/11.


Vitamin C Soothes Pain from Osteoarthritis in 14 days

July 6, 2003

Vitamin C soothes pain from osteoarthritis in 14 days. That is the conclusion of a Danish scientific study recently published in the Danish medical magazine, Ugeskrift for Laeger.

133 patients with osteoarthritis of the hip joint and knee joint were treated with one gram of vitamin C or placebo twice daily for 14 days. In those who got vitamin C there was clearly better pain relief than in the other group.

The study was made because many people have said that vitamin C has helped with their osteoarthritis.

“Our study, which have been carried out to the highest scientific standard, have shown that vitamin C reduces the pain of osteoarthritis of the hip or knee joint within 14 days,” says Niels Hertz, specialist in general medicine.

“This effect was statistically exceptionally safe and led to very clear improvements in the functioning of those with arthritis. The magnitude of the effect is equivalent to half what you normally find with arthritis pills (NSAIDs), but unlike these, the treatment with vitamin C is free of side effects and can be tolerated indefinitely.

The finding is extra interesting because other studies have shown that people with arthritis who get a lot of vitamin C do not worsen as much over time as those who get ordinary Danish average amounts. This was found a few years ago in the famous American Framingham study, a result that attracted attention at the time.

In other words, one can imagine that vitamin C not only relieves the pain of osteoarthritis, but also counteracts aggravation of arthritis!

There are many examples of this happening. A retired nurse, I know, meant for approx. 10 years ago that she could no longer avoid a hip operation. She was in so much pain. Then she started taking vitamin C and today she is still not operated on. I see her regularly on the street, without a cane and in a good mood.

Every twentieth Dane receives less than 30 mg of vitamin C a day, and very few come close to the American averages from Framingham. This is highly unfortunate for public health.

Several of the world’s leading experts in vitamin C believe that the recommended daily allowances (RDA) should be significantly increased.

Vitamin C is, in my opinion, a fantastically exciting vitamin, which most likely has several other positive surprises in it. We are far from finished exploring it, ”concludes Niels Hertz.

By: Vitality Council

Jensen, Niels H.P. Hertz, Ugeskr Laeger 2003;165:2563-6.

Vitamins in general, Research references

January 1999

1. Ames BN, Berkeley, Univ. CA et al. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased K-m): relevance to gentic disease and polymorphisms. Am J Clin Nutr, 2002, vol.75, 616-58.
2. Fairfield KM, Fletcher RH, Harvard Medical School, Vitamins for Chronic Disease Prevention in Adults, Scientific Review, JAMA, vol. 287, 3116-26, 2002. (152 refs.)
3. Fletcher RH, Fairffield KM, Vitamins for Chronic Disease Prevention in Adults, Clinical Applications, JAMA, vol. 287, 3127-29, 2002. (23 refs.)


Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.

Coenzyme Q10, Research references

January 1999

1. Battino M, Fato R, Lenaz G: Coenzyme Q10 can control the efficiency of oxidative phosphorylation.; Int J Tissue React 12, no. 3, pp. 137-144, 1990.
2. Chen Rou-Shayn et al. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Eur Neurol 37:212-18, 1997.
3. Folkers K et al. Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10. Proc Natl Acad Sci U S A 82;13:4513-16, 1985.
4. Folkers K, Wolaniuk J, Sinonsen R, et al, in K. Folkers, Y Yamamura, Eds. Biochemical and Clinical Aspects of Coenzyme Q10, Vol. 5. Amsterdam, Elsevier Science Pub. 353-8, 1985
5. Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci U S A 1985;82:901-4
6. Folkers K, Langsjoen P, Nara Y, et al. Biochemical deficiencies of coenzyme Q10 in HIV-infection and exploratory treatment. Biochem Biophys Res Commun 153:888-96, 1988.
7. Folkers K, Hanioka T, Xia LJ, et al. Coenzyme Q10 increases T4/T8 ratios of lymphocytes in ordinary subjects and relevance to patients having the AIDS-related complex. Biochem Biophys Res Commun 176; (2):786-91, 1991.
8. Folkers K, Morita M, McRee Jr. J. The activities of coenzyme Q10 and vitamin B6 for immune response. Biochem Biophys Res Commun 193: 88-92, 1993.
9. Fryburg DA et al. The immunostimulatory effects and safety of beta-carotene in patients with AIDS. VIIIth Int Conf on AIDS, Amsterdam, 1992.
10. Sato K. Pharmacoklinetics of coenzyme Q10 in recovery of acute sensorineural hearing loss due to hypoxia. Acta Otolaryngol Suppl (Stockh.) 458: 95-102, 1988.
11. Simonsen R, Folkers K, Komorowski J, et al, in K Folkers, GP Littarru, T Yamagami, Eds. Biochemical and Clinical Aspects of Coenzyme Q10, Volume 6. Amsterdam, Elsevier Science Publ., 363-73, 1991.
12. Sobreira C et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology 48:1238-43, 1997.
13. Yamabe H, Fukuzaki H, in K Folkers, GP Littarru, Y Yamagami, Eds. Biochemical and Clinical Aspects of Coenzyme Q10, Vol. 6. Amsterdam, Elsevier Sci Pub., 1991: 541-5, 1991.
14. Zeppilli P, Merlino B, DeLuca A, et al, in K Folkers, GP Littarru, Y Yamagami, Eds. Biochemical and Clinical Aspects of Coenzyme Q10, Volume 6. Amsterdam, Elsevier Science Pub. 541-5, 1991.
15. Judy, W.V., Folkers, K.A., & Stogsdill, W.W. (1993). Myocardial preservation by therapy with Coenzyme Q10 during heart surgery. Clinical Investigator; 71(8 Suppl): S155-61.
16. Morisco, C., Trimarco, B., & Condorelli, M. (1993). Effect of Coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. The Clinical Investigator, 71(8 Suppl), S134-S136.


Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach, and others


Minerals in general, Research references

January 1999

1. Green TJ, Whiting SJ. Potassium bicarbonate reduces high protein-induced hypercalciuria in adult men. Nutr Res 14:991-1002, 1994.
2. Heyburn PJ et al. Phosphate treatment of recurrent calcium stone disease. Nephron 32, 4:314-19, 1982.
3. Khanniazi MK, Khanam A, Japper Naqvi SA, Sheikh MA. Study of potassium citrate treatment of crystalluric nephrolithiasis. Biomed Pharmacother 47:25-8, 1993.
4. Moss M. Effects of molybdenum on pain and general health: A pilot study. J Nutr Environ Med 5: 55-61, 1995.
5. Munthe E, Aaseth J, Jellum E. Trace elements and rheumatoid arthritis (RA) – pathogenetic and therapeutic aspects. Acta Pharmacol Toxicol (Copenh) 7: 365-73, 1986.
6. Newnham RE. Trace element in man and animals -5. Abstracts. Aberdeen, Scotland. 1984: p 26.
7. Niedermeier W, Griggs JH. Trace metal composition of synovial fluid and blood serum of patients with rheumatoid arthritis. J Chronic Dis 23: 527-36, 1971.
8. Norbiato G et al. Effects of Potassium Supplementation on Insulin Binding and Insulin Action in Human Obesity: Protein-Modified Fast and Refeeding. Europ J Clin Invest 44: 414-19, 1984.
9. Pak CYC et al. Long term treatment of calcium nephrolithiasis with potassium citrate. J Urol 134, 1:11-19, 1985.
10. Pak CY, Fuller C. Idiopathic hypocitraturic calcium-oxalate nephrolithiasis successfully treated with potassium citrate. Ann Intern Med 104, 1:33-7, 1986.
11. Pak CY, Peterson R. Successful treatment of hyperuricosuric calcium oxalate nephrolithiasis with potassium citrate. Arch Intern Med 146, 5:863-7, 1986.
12. Palmqvist E, Tiselius HG. Phosphate treatment of patients with renal calcium stone disease. Urol Int 43; 1:24-8, 1988.
13. Preminger GM et al. Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with renal tubular acidosis. J Urol 134; 1:20-3, 1985.
14. Preminger GM et al. Alkali action on the urinary crystallization of calcium salts: Contrasting responses to sodium citrate and potassium citrate. J Urol 139; 2:240-2, 1988.
15. Rajagopalan KV. Molybdenum: An essential trace element in human nutrition. Ann Rev Nutr 8: 401-27, 1988.
16. Saltman, P.D. & Strause, L.G.: The Role of Trace Minerals in Osteoporosis; Journal of the American College of Nutrition 12, ss. 384, 1993.
17. Schauss A. Minerals, trace elements and human health. 3rd edn. Tacoma, WA: AIBR Life Sciences. 1997.
18. Sandstead HH. Trace element interactions. J Lab Clin Med 98: 457-462, 1981.
19. Vijaya I et al. Trace metal analysis in the aorta with and without atherosclerotic lesions. Trace Elem Electrolytes 12;4:200-2, 1995.


Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.

Calcium, Research references

January 1999

1. Adams P, Davies GT, Sweetnam P. Osteoporosis and the effects of aging on bone mass in elderly men and women. J Med New Series 39: 601-615, 1970.
2. Angus RM, Sambrook PN, Pocock NA, Eisman JA. Dietary intake and bone mineral density. Bone Miner 4: 265-277, 1988.
3. Arnaud, DC, Sanchez, SD. Calcium and phosphorous. Present knowledge in nutrition. 6th edn. Washington DC: Nutrition Foundation. p 212-221, 371-373, 1990.
4. Arnaud CD, Sanchez SD. The role of calcium in osteoporosis. Ann Rev Nutr 10: 397-414, 1990.
5. Bhat KS. Plasma calcium and trace minerals in human subjects with mature cataract. Nutr Rep Int 37:157-63, 1988.
6. Calcium pantothenate in arthritic conditions. A report from the General Practitioner Research Group. Practitioner 224: 208-11, 1980.
7. Chu lY, Margen S, Costa FM. Studies in calcium metabolism. Am J Clin Nutr 28: 1028-1035, 1975.
8. Cook J, Dassenko S, Whittaker P. Calcium supplementation. Effect on iron absorption. Am J Clin Nutr 53: 106-111, 1991.
9. Dawson-Hughes B, Jacques P, Shipp C. Dietary calcium intake and bone loss from the spine in healthy postmenopausal women. Am J Clin Nutr 46: 685-687, 1987.
10. Desai S, Baran D, Grimes J et al. Relationship of diet, axial, and appendicular bone mass in normal premenopausal women. Am J Med Sci 293: 218-220, 1987.
11. Elders PJ, Netelenbos JC, Lips P et al. Perimenopausal bone mass and risk factors. Bone Miner 7: 289-299, 1989.
12. Ettinger, B. Role of Calcium in Preserving the Skeletal Health of Aging Women; Southern Medical Journal,  85; (8); 2S22-30, Aug. 1992.
13. Fletcher MP et al. Nutrition and immunology. New York: Alan R. Liss. p 215-239, 1988.
14. Freudenheim JL, Johnson NE, Smith EL. Relationships between usual nutrient intake and bone-mineral content of women 35-65 years of age. Longitudinal and cross-sectional analysis. Am J Clin Nutr 44: 863-876, 1986.
15. Garn SM, Rohmann CG, Wagner B. Continuing bone growth through life. A general phenomenon. Fed Proc 26: 1729-1736, 1967.
16. Goldman L. Treatment of subacute and chronic discoid lupus erythematosus with intensive calcium pantothenate therapy. J Invest Dermatol 11: 95, 1948.
17. Hallberg L, Brune M, Erlandsson M et al. Calcium. Effect of different amounts on nonheme- and heme-iron absorption in humans. Am J Clin Nutr 53: 112-119, 1991.
18. Heaney RP, Recker RR, Saville PD. Calcium balance and calcium requirements in middle-aged women. J Lab Clin Med 92: 964-70, 953-963, 1978.
19. Jowsey J. Osteoporosis. dealing with a crippling bone disease of the elderly. Geriatrics 32: 41-50, 1977.
20. Kanis JA, Passmore R. Calcium supplementation of the diet – I. Br Med J 298: 137-140, 1989.
21. Kanis JA, Passmore R. Calcium supplementation of the diet II. Br Med J 298: 205-208, 1989.
22. Kanders B, Dempster DW, Lindsay R. Interaction of calcium nutrition and physical activity on bone mass in young women. J Bone Miner Res 1988; 3: 145-149.
23. Laval-Jeanet AM, Paul G, Bergot C et al. Correlation between vertebral bone density measurement and nutritional status. In: Proceedings – osteoporosis. Glostrup: Glostrup Hospital. p 953-963, 1984.
24. Linkswiler HM, Joyce CL, Anand CR. Calcium retention of young adult males as affected by level of protein & of calcium intake. Trans NY Acad Sci 36: 333-340, 1974.
25. Mazess RB, Barden HS. Bone density in premenopausal women: Effects of age, dietary intake, physical activity, smoking, and birth-control pills. Am J Clin Nutr 53: 132-142, 1991.
26. New england – Heany, R.P.: Thinking straight about Calcium; New England Journal of Medicine; 328, ss. 503, 1993.
27. Nilas L, Christiansen C, Rodbro P. Calcium supplementation and postmenopausal bone loss. Br Med J 1984; 289: 1103-1106, 1984.
28. Nordin BE, Polley KJ. Metabolic consequences of the menopause. A cross-sectional, longitudinal, and intervention study on 557 normal postmenopausal women. Calcif Tissue Int 41: 1-59, 1987.
29. Penland JG and Johnson PE, Dietary Calcium and Manganese Effects on Menstrual  Cycle Symptoms, Am J Obstet Gynecol 168; 1417-23, 1993.
30. Riggs BL, Wahner HW, Melton LJ 3rd et al. Dietary calcium intake and rates of bone loss in  women. J Clin Invest 80: 979-982, 1987.
31. Riis B, Thomsen K, Christiansen C. Does calcium supplementation prevent post menopausal bone loss? A double-blind, controlled clinical study. New Eng J Med 316: 173-177, 1987.
32. Sowers MR, Wallace RB, Lemke JH. Correlates of forearm bone mass among women during maximal bone mineralization. Prev Med 14: 585-596, 1985.
33. Sowers MR, Wallace RB, Lemke JH. Correlates of mid-radius bone density among postmenopausal women. A community study. Am J Clin Nutr 41: 1045-1053, 1985.
34. Spencer H, Karmer L et al. Effect of a high protein (meat) intake on calcium metabolism in man. Am J Clin Nutr 31: 2167-2180, 1978.
35. Stevenson JC, Whitehead MI, Padwick M et al. Dietary intake of calcium and postmenopausal bone loss. Br Med J 297: 15-17, 1988.
36. Tylavsky FA, Anderson JJ. Dietary factors in bone health of elderly lactoovovegetarian and omnivorous women. B. Am J Clin Nutr 1988; 48: 842-849, 1988.
37. Van Beresteijn EC, van’t Hof MA, de Waard H. Relation of axial bone mass to habitual calcium intake and to cortical bone loss in healthy early postmenopausal women. Bone 11: 7-13, 1990.
38. Webb RC, Bohr DF. Mechanism of membrane stabilization by calcium in vascular smooth muscle. Am J Physiol 235: C227, 1978.
39. Calcium, vitamin D, milk consumption, and hip fractures: a prospective study among postmenopausal women. Diane Feskanich, Walter C Willett, and Graham A Colditz. Am J Clin Nutr 2003;77 504-511


Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.

Iron, Research references

  1. Allen, LH. Pregnancy and iron deficiency. Unresolved issues. Nutr Rev 1997; 55: 91-100.
  2. Anonymous. Vitamin A deficiency and anemia. Nutr Rev 1979; 37: 38-40.
  3. Anonymous. Vitamin A deficiency and iron nutriture. Nutr Rev 1984; 42: 167-168.
  4. Ballin A, Berar M, Rubinstein U, et al. Iron state in female adolescents. Am J Dis Child 146(7): 803-5, 1992.
  5. Ballott DE, MacPhail AP, Bothwell TH et al. Fortification of curry powder with NaFe(111) EDTA in an iron-deficient population. Initial survey of iron status. Am J Clin Nutr 1989; 49: 156-161.
  6. Bates CJ et al. Vitamins, iron, and physical work. Lancet ii: 313-14, 1989.
  7. Beard, JL, Dawson H, Pinero, DJ. Iron metabolism. A comprehensive review. Nutr Rev 1996; 54: 295-317.
  8. Beutler E, Larsh SE, Gurney CW. Iron therapy in chronically fatigued, nonanemic women; a double-blind study. Ann Intern Med 1960; 52: 378-394.
  9. Blake DR et al. The importance of iron in rheumatoid disease. Lancet ii: 1142-4, 1981.
  10. Blake DR et al. Effect of intravenous iron dextran on rheumatoid synovitis. Ann Rheum Dis 44: 183-8, 1985.
  11. Buetler E, Larsh SE, Gurney CW. Iron therapy in chronically fatigued non-anemic women: A double blind study. Ann Intern Med 52: 378-94, 1960.
  12. Chua ACG, Morgan EH. Effects of iron deficiency and iron overload on manganese uptake and deposition in the brain and other organs of the rat. Biol Trace Elem Res 1996; 55: 39-54.
  13. Cook J, Dassenko S, Whittaker P. Calcium supplementation. Effect on iron absorption. Am J Clin Nutr 1991; 53: 106-111.
  14. Dallman PR, Beutler E, Finch CA. Effects of Iron deficiency exclusive of anaemia Br J Haematol 1978; 40: 179-184.
  15. Dallman, PR. Iron. In: Present knowledge in nutrition. 6th edn. Washington DC: Nutrition Foundation. 1990: p 241-250.
  16. Dalton MA et al. Calcium and phosphorous supplementation of iron-fortified infant formula. No effect on iron status of healthy full-term infants. Am J Clin Nutr 1997; 65: 921-926.
  17. Edgerton VR, Ohira Y et al. Toleration of hemoglobin and work tolerance in iron deficient subjects. J Nutr Sci Vitaminol 1981; 27: 77-86.
  18. Fairweather Tait SJ, Minihane AM, Eagles J et al. Rare earth elements as nonabsorable fecal markers in studies of iron absorption. Am J Clin Nutr 1997; 65: 970-976.
  19. Dabbagh AJ. Trenam CW, Morris CJ, Blake DR. Iron in joint inflammation. Ann Rheum Dis 52:67-73, 1993.
  20. Dabbagh AJ. Trenam CW, Morris CJ, Blake DR. Iron in joint inflammation. Ann Rheum Dis 52:67-73, 1993.
  21. Davidson A et al. Red cell ferritin content: A re-evaluation of indices for iron deficiency in the anaemia of rheumatoid arthritis. Br Med J 289: 648-50, 1984.
  22. Gardner GW et al. Physical work capacity and metabolic stress in subjects with iron deficiency anemia. Am J Clin Nutr 30; 6: 910-17, 1977.
  23. Gleerup A, Rossander-Hulthen L, Gramatkovski E et al. Iron absorption from the whole diet: comparison of the effect of two different distributions of daily calcium intake. Am J Clin Nutr 1995; 61: 97-104.
  24. Green R, Charlton R et al. Body iron excretion in man; a collaborative study. Am J Med 1968; 45: 336-353.
  25. Hallber L. Bioavailability of dietary iron in man. Ann Rev Nutr 1981; 1: 123-147.
  26. Hallberg L, Nilsson L. Constancy of individual menstrual blood loss. Acta Obstet Gynecol Scand 1964; 43: 352-359.
  27. Hallberg L, Rossander L, Persson H. Deleterious effects of prolonged warming of meals on ascorbic acid content and iron absorption. Am J Clin Nutr 1982; 36: 846-850.
  28. Hallberg L, Brune M, Erlandsson M et al. Calcium. Effect of different amounts on nonheme- and heme-iron absorption in humans. Am J Clin Nutr 1991; 53: 112-119.
  29. Hansen TM et al. Serum ferritin and the assessment of iron deficiency in rheumatoid arthritis. Scand J Rheumatol 12; 4: 353-9, 1983.
  30. Hansen TM, Hansen NE. Serum ferritin as indicator of iron responsive anemia in patients with rheumatoid arthritis. Ann Rheum Dis 45: 569, 1986.
  31. Hunt, JR, Gallagher, SK, Johnson, LK. Effect of ascorbic acid on apparent iron absorption by women with low iron stores. Am J Clin Nutr 1994; 59: 1381-1385.
  32. Kent S, Weinberg E. Hypoferremia. Adaptation to disease? New Eng J Med 1989; 320: 672.
  33. Kies C, ed. Nutritional bioavailability of iron. Washington, DC: American Chemical Society. 1982.
  34. Kies, C, Bylund, DM. Iron status of adolescent boys and girls as influenced by variations in dietary ascorbic acid and iron intakes. Nutr Rep Intl 1989; 40: 43-51.
  35. Li R, Chen X, Yan H, et al. Functional consequences of Iron Supplementation in iron-deficient female cotton mill workers in Beijing, China. Am J Clin Nutr 59: 908-13, 1994.
  36. Lynch, SR. Interaction of iron with other nutrients. Nutr Rev 1997; 55: 102-110.
  37. Magnusson B, Bjorn-Rasmussen E, Hallberg L et al. Iron absorption in relation to iron status. Model proposed to express results of food iron absorption measurements. Scand J Haematol 1981; 27: 201-208.
  38. McCord, JM. Effects of positive iron status at a cellular level. Nutr Rev 1996; 54: 85-88.
  39. Muirden KD, Senator GB. Iron in the synovial membrane in rheumatoid arthritis and other joint diseases. Ann Rheum Dis 27: 38-48, 1968.
  40. Ohira Y, Edgerton VR, Gardner GW et al. Work capacity after iron treatment as a function of hemoglobin and iron deficiency. J Nutr Sci Vitaminol 1981; 27: 87-96.
  41. Oski FA, Honig AS, Helu B, Howanitz P. Effect of iron therapy on behavior performance in nonanemic, iron-deficient infants. Pediatrics 1983; 71: 877-880.
  42. Oski FA, Honig AS. The effects of therapy on the developmental scores of iron deficient infants. J Pediatr 1978; 92: 21-25.
  43. Pollitt E, Leibel RL. Iron deficiency and behavior. J Pediatr 1976; 88: 372-381.
  44. Pollitt E, Leibel RL, Greenfield DB. Iron deficiency and cognitive test performance in preschool children. Nutr Behavior 1983; 1: 137-146.
  45. Pollitt E, Soemantri AG, Yunis F, Scrimshaw NS. Cognitive effects of iron-deficiency anaemia. Lancet 1985; 1: 158.
  46. Prasad MK, Pratt CA. The effects of exercise and two levels of dietary iron on iron status. Nutr Res 1990; 10: 1273-1283.
  47. Rothwell RS, Davis P. Relationship between serum ferritin, anemia, and disease activity in acute and chronic rheumatoid arthritis. Rheumatol Int 1; (2): 65-7, 1981.
  48. Scrimshaw NS. Functional consequences of iron deficiency in human populations. J Nutr Sci Vitaminol 1984; 30: 47-63.
  49. Sempos, CT, Looker, AC, Gillum, RF. Iron and heart disease. The epidemiologic data. Nutr Rev 1996; 54: 73-88.
  50. Sheard, NF. Iron deficiency and infant development. Nutr Rev 1994; 52: 137-140.
  51. Stãhlberg MR, Savilahti E, Siimes MA. Iron deficiency in coeliac disease is mild and it is detected and corrected by gluten-free diet. Acta Paediatr Scand 80; (2):190-3, 1991.
  52. Tucker DM, Sandstead HH, Penland JG et al. Iron status and brain function: serum ferritin levels associated with asymmetries of cortical electrophysiology and cognitive performance. Am J Clin Nutr 1984; 39: 105-113.
  53. Voorhees ML, Stuart MJ et al. Iron deficiency anemia and increased urinary norepinephrine. J Pediatr 1g74; 86: 542-547.
  54. Vreugdenhil G et al. Efficacy and safety of oral iron chelator L1 in anaemic rheumatoid arthritis patients. Letter. Lancet ii: 1398-9, 1989.
  55. Walter T, Olivares M, Pizarro F et al. Iron, anemia, and infection. Nutr Rev 1997; 55: 111-124.
  56. Webb TE, Oski FA. Iron deficiency anemia and scholastic achievement in young adolescents. J Pediatr 1973; 82: 827-830.
  57. Webb TE, Oski FA. Behavioral status of young adolescents with iron deficiency anemia. J Spec Educ 1974; 8: 153-156.
  58. Willis WT et al. Iron deficiency: Improved exercise performance within 15 hours of iron treatment in rats. J Nutr 120; 8: 909-16, 1990.
  59. Yip, R, Dallman, PR. Iron. In: Present knowledge in nutrition. 7th edn. Washington, DC: Nutrition Foundation. 1996: p 277-292.
  60. Zittoun J, Blot 1, Hill C et al. Iron supplements versus placebo in pregnancy. Its effects on iron and folate status on mothers and newborns. Ann Nutr Metabol 1983; 27: 320-327.

Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.

Iodine, Research References

January 1999

1. Eskin B.A. et al. Mammary Gland Dysplasia in Iodine Deficiency, JAMA 200; 691-5, 1967.
2. Ghent W.R. et al. Iodine Replacement in Fibrocystic Disease of the Breast, Can J Surg 36; 453-60, 1993.
3. Hetzel, SC. Present knowledge in nutrition. 6th edn. Iodine deficiency. An international public health problem. Washington DC: Nutrition Foundation. p 308-312, 1990.
4. Hetzel, B.S. Iodine deficiency and fetal brain damage. N Eng J Med. 331: 1770-1771, 1994.
5. Hunnikin C, Wood FO. Endemic goiter and endemic cretinism. New York: John Wiley. p 497-512, 1980.
6. Kearny, CH, Orient, JM. Thyroid protection. Science. 274: 1596-1597, 1996.
7. Matovinovic J, Trowbridge FL. Endemic goiter and endemic cretinism. New York: John Wiley. p 37-67, 1980.
8. Matovinovic J. Endemic goiter and cretinism at the dawn of the third millenium. Ann Rev Nutr 3: 341-412, 1983.
9. Stanbury, JB. Iodine deficiency and the iodine deficiency disorders. In: Present knowledge in nutrition. 7th edn. Iodine. Washington, DC: Nutrition Foundation. p 378-383, 1996.
10. Wang YY, Yang SH. Improvement in hearing among otherwise normal schoolchildren in iodine-deficient areas of Guizhou China, following use of iodized salt. Lancet 2: 518-520, 1985.
11. Xue-Yi C, Xin-Min J, Zhi-Hong D et al. Timin of vulnerability of the brain to iodine deficiency in endemic cretinism. N Eng J Med. 331: 1739-1744, 1994.

Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.

Chromium, Research references

January 1999

1. Anderson RA, Polansky MM, Bryden NA et al. Urinary chromium excretion of human subjects. Effects of chromium supplementation and glucose loading. Am J Clin Nutr 36: 1184 1193, 1982.
2. Anderson RA, Polansky MM, Bryden NA, Patterson KY, Veillon C, Glinsmann. Effects of chromium supplementation on urinary Cr excretion with selected clinical parameters. J Nutr, 113: 276-281, 1983.
3. Anderson RA et al. Chromium supplementation of humans with hypoglycemia. Fed Proc 43:471, 1984.
4. Anderson RA, Polansky MM, Bryden NA. Acute effects on chromium, copper, zinc and selected clinical variables in urine and serum of male runners. Biol Trace Elem Res 6: 327-336, 1984.
5. Anderson RA, Kozlovsky AS. Chromium intake, absorption and excretion of subjects consuming self-selected diets. Am J Clin Nutr 42: 1177-1183, 1985.
6. Anderson RA. Chromium metabolism and its role in disease processes in man. Clin Physiol Biochem, 4: 31 41, 1986.
7. Anderson RA, Polansky MM, Bryden NA, et al.: Effects of supplemental chromium on patients with symptoms of reactive hypoglycemia. Metabolism 36; 4:351-5, 1987.
8. Anderson RA. Chromium and its role in lean body mass and weight reduction. Nutrition Report 11: 41, 46, 1991.
9. Anderson RA: Chromium, glucose tolerance, and diabetes.; Biol Trace Elem Res 32, pp. 19-24, 1992.
10. Anderson R et al. Beneficial Effect of Chromium for People with Type II Diabetes. Diabetes 45; suppl. 2; 124A/454, 1996.
11. Baker B. Chromium Supplements Tied to Glucose Control. Family Practice News; 5; July 15, 1996.
12. Borel JS, nderson RA. Biochemistry of the essential ultratrace elements. New York: Plenum. p 175-199, 1984.
13. Brewer G, Turkay A, Yuzbasiyan-Gurkan V, Barnett J. Chromium supplementation and insulin sensitivity in psoriasis. Abstract. J Am Coll Nutr 12:588, 1993.
14. Bunker VW, Lawson MS, Delves HT, Clayton BE. The intake and excretion of chromium by the elderly. Am J Clin Nutr 39: 799-802, 1984.
15. Clausen J. Chromium induced clinical improvement in symptomatic hypoglycemia. Biol Trace Elem Res 17:229-36, 1988.
16. Donaldson DL, Rennert OM. Metabolism of trace elements in man, vol. 2: genetic implications. Boca Raton, FL: CRC Press. p 113-132, 1984.
17. Evans GW, Ropginksi EE, Mertz W. Interaction of the glucose tolerance factor (GFW) with insulin. Biochem Biophys Res Commun 1973; 50: 718-722, 1973.
18. Evans GW. The effect of chromium picolinate on insulin controlled parameters in humans. Int J Biosocial Med Res 11: 163-180, 1989.
19. Gibson RS, Scythes CA. Chromium, selelnium and other trace element intakes of a selected sample of Canadian premenopausal women. Biol Trace Eleme Res 6: 105-116, 1984.
20. Gordon JB. An easy and inexpensive way to lower cholesterol? West J Med 154: 3, 1991.
21. Kozlovsky AS, Moser PB, Reiser S, Anderson RA. Effects of diets high in simple sugars on urinary chromium losses. Mctabolism 35: 515-518, 1986.
22. Lefavi R. Lipid-lowering effects of a dietary nicotinic acid-chromium III complex in male athletes. FASEB J 5;6:A1645, 1991.
23. Lefavi R et al. Lipid-lowering effect of a dietary chromium III-nicotinic acid complex in male athletes. Nutr Res 13:239-49, 1993.
24. Levine R et al. Effect of Oral chromium Supplementation of the Glucose Tolerance of Elderly Human Subjects. Metabolism 17; 114-25, 1968.
25. Menendez CE, Stoecker BJ. Nutrition and diabetes. New York: Alan R. Liss. p 15-36, 1985.
26. Offenbacher EG, Pi-Sunyer FX. Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjects. Diabetes 29: 919, 1980.
27. Offenbacher EG, Rinko CJ, Pi-Sunyer FX. The effects of inorganic chromium and brewer’s yeast on glucose tolerance, plasma lipids, and plasma chromium in elderly subjects. Am J Clin Nutr 42: 454-456, 1985.
28. Offenbacher EG, Pi-Sunyer FX. Chromium in human nutrition. Ann Rev Nutr 8: 543-563, 1988.
29. Pekarek RS, Hayer EC, Rayfield EJ et al. Relationship between serum chromium concentrations and glucose utilization in normal and infected subjects. Diabetes 24: 350 353, 1975.
30. Press RI, Geller J, Evans GW. The effect of chromium picolinate on serum cholesterol and apolipoprotein fractions in human subjects. West J Med 152: 41-45, 1990.
31. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595 1607, 1988.
32. Schroeder HA. The role of chromium in mammalian nutrition. Am J Clin Nutr 21: 230-244, 1968.
33. Seaborn CD, Stoecker BJ. Effects of antacid or ascorbic acid on tissue accumulation and urinary excretion of 51chromium. Nutr Res 10: 1401-1407, 1990.
34. Simonoff M, Llabador Y, Hamon C et al. Low plasma chromium in patients with coronary artery and heart disease. Biol Trace Elem Res 6: 431-439, 1984.
35. Stoecker, BJ Present knowledge in nutrition. 6th edn. Chromium. Washington DC: Nutrition Foundation. p 287-291, 1990.
36. Stoecker BJ. Chromium. In: Present knowledge in nutrition. 7th edn. Washington, DC: Nutrition Foundation. p 344-352, 1996.
37. Urberg M, Parent M, Mill D et al. Evidence for synergism between chromium and nicotinic acid in normalizing glucose tolerance. Diabetes 1986; 35: 37a.
38. Urberg M et al. Hypocholesterolemic effect of nicotinic acid and chromium supplementation. J Fam Pract 27;6:603-6, 1988.
39. Uusitupa MI, Kumpulainen JT, Voutilainen E, Hersio K, Sarlund H, Pyorala KP, Koivistoinen PE, Lehto JT. Effect of inorganic chromium supplementation on glucose non-insulin-dependent diabetics. Am J Clin Nutr 38: 404-410, 1983.
40. Wang M, Fox E, Stoecker B. Serum cholesterol of adults supplemented with brewer’s yeast or chromium chloride. Nutr Res 9: 989-998, 1989.
41. Wedrychowski A, Ward WA, Schmidt WN, Hnilica LS. Chromium-induced cross-linking of nuclear proteins and DNA. J Biol Chem 260: 7150-7155, 1985.
42. Wolf W, Mertz W, Masironi R. Determination of chromium in refined and unrefined sugars. J Agr Food Chem 22: 1037-1042, 1974.

Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.

Copper, Research references

January 1999

1. Anonymous. Copper affects atherosclerosis. Med Tribune 1991; 32: 6.
2. Banford JC et al. Serum Copper and Erythrocyte Superoxide Dismutase in Rheumatoid Arthritis. Ann Rheum Dis 41; 5: 458-62, 1982.
3. Bland, J. Copper salicylates and complexes in molecular medicine. Int Clin Nutr Rev 4; 3: 130-4, 1984.
4. Conforti A, Franco L, Menegale G, et al. Serum copper and ceruloplasmin levels in rheumatoid arthritis and degenerative joint disease and their pharmacological implications. Pharmacol Res Commun 15; 9: 859-67, 1983.
5. Dowdy RP. Copper metabolism. Am J Clin Nutr 1969; 22: 887.
6. Evans GW. Copper homeostasis in the mammalian system. Physiol Rev 1973; 53: 535.
7. Fields M, Ferretti RJ, Smith JC Jr, Reiser S. The interaction of type of dietary carbohydrates with copper deficiency. Am J Clin Nutr 1984; 39: 289-295.
8. Fletcher MP, Gershwin ME, Keen CL et al. Trace element deficiences and immune responsiveness in human and animal models. In: Chandra RK, ed. Nutrition and immunology. New York: Alan R. Liss. 1988: p 215-239.
9. Goyens P et al. Copper deficiency in infants with active celiac disease. J Pediatr Gastroenterol Nutr 4; (4):677-80, 1985.
10. Grennan DM et al. Serum copper and zinc in rheumatoid arthritis and osteoarthritis. N Z Med J 91; 652: 47-50, 1980.
11. Hangarter W. Copper salicylate in rheumatoid arthritis and rheumatism-like degenerative diseases. Med Welt 31:1625, 1980.
12. Honkanen VEA et al. Plasma zinc and copper concentrations in rheumatoid arthritis: Influence of dietary factors and disease activity. Am J Clin Nutr 54: 1082-6, 1991.
13. Jacka T et al. Copper salicylate as an anti-inflammatory and analgaesic agent in arthritic rats. Life Sci 32: 1023, 1983.
14. Jameson S et al. Copper malabsorption in coeliac disease. Sci Total Environ 42; (1-2):29-36, 1985.
15. Kelley DS, Dauda PA, Taylor PC et al. Effects of low-copper diets on human immune response. Am J Clin Nutr 19g5; 62: 412-416.
16. Kishore V et al. Effect of a nutritional copper deficiency on the development of adjuvant arthritis in the rat, in DD Hemphill, Ed. Trace Substances in Environmental Health XVI. Columbia, MO, U. of Missouri, 1982.
17. Klevay LM. Metabolism of trace metals in man, vol. 1. Boca Raton, FL: CRC Press. 1984: p 129-157.
18. Linder M.C. Copper. In: Present knowledge in nutrition. 7th edn. Washington, DC: Nutrition Foundation. 1996: p 307-319.
19. Lynch S, Klevay L. Effects of a dietary copper deficiency on plasma coagulation factor activities in male and female mice. J Nutr Biochem 3:387, 1992.
20. Mussalo-Rauhamaa H et al. Predictive clinical and laboratory parameters for serum zinc and copper in rheumatoid arthritis. Ann Rheum Dis 47; (10): 816-19, 1988.
21. Niedermeier W. Concentration and chemical state of copper in synovial fluid and blood serum of patients with rheumatoid arthritis. Ann Rheum Dis 24: 544, 1965.
22. O’Dell BL. Copper. In: Present knowledge in nutrition. 6th edn. Washington DC: Nutrition Foundation. 1990: p 261-265.
23. Okuyama S et al. Copper complexes of non-steroidal antiinflammatory agents: Analgesic activity and possible opioid receptor activation. Agents Actions 21; (1-2): 130-44, 1987.
24. Percival S.S. Neutropenia caused by copper deficiency. Possible mechanisms of action. Nutr Rev 1995; 53: 59 66.
25. Pocino M, Baute L, Malav’e I. Influence of oral administration of excess copper on the immune response. Fund Appl Therap 1991; 16: 249-256.
26. Posacki C, et al. Plasma, Copper, Zinc, and Magnesium Levels in Patients with Premenstrual Tension Syndrome, Acta syndrome : Obstet Gynecol Scand 73 : 452-5, 1994.
27. Reunanen A, Knekt P, Marniemi J et al. Serum calcium, magnesium, copper and zinc and risk of cardiovascular death. Eur J Clin Nutr 50: 431-437.
28. Schroeder HA, Nason AP, Tipton IH. Essential trace metals in man. J Chron Dis 1966; 19: 1007-1034.
29. Sorenson JRJ. Copper chelates as possible active forms of anti-arthritic agents. J Med Chem 19: 135, 1976.
30. Sorenson JRJ, Hangarter W. Treatment of Rheumatoid and Degenerative Diseases with Copper Complexes: A review with Emphasis on Copper-salicylate. Inflammation 2; 3: 217-38, 1977.
31. Sorenson JRJ. Copper complexes: A unique class of anti-arthritic drugs. Prog Med Chem 15: 211, 1978.
32. Sorenson JRJ. The Anti-inflammatory Activities of Copper Complexes, Metal Ions and Biological Systems. Marcel Dekker, 1982: 77-125.
33. Stemmer KL, Petering HG, Murthy L et al. Copper deficiency effects on cardiovascular systems and lipid metabolism in the rat the role of dietary proteins and excessive zinc. Ann Nutr Metabol 1985; 29: 332-347.
34. Watts DL. The nutritional relationships of copper. J Orthomol Med 4(2): 99-108, 1989.
35. Youssef AA et al. Serum copper: A marker of disease activity in rheumatoid arthritis. J Clin Pathol 36; 1: 14-17, 1983.
36. Zelkowitz M, Verghese JP, Antel J. Zinc and copper in medicine. Springfield IL: Charles C. Thomas. 1980: p 418-463.

Joseph E. Pizzorno Jr., Michael T. Murrey & Melvyn R. Werbach.